Lantern Pharma (LTRN) announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer, or TNBC. This marks the second Fast Track Designation received for LP-184 in 2024, following its designation for Glioblastoma in October.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN: